Recommendations first.
The provenance alongside.

Recommendation coverage.

Newborn critical congenital heart defect (CCHD) screening has 14 local reference entries and a static factual table of CDC’s current screening flow. The CDC clinical page (updated/reviewed October 14, 2026) and its hosted 2025 algorithm were read, including timing/oxygen gates, both-site passing, immediate failure, one-hour retest, endpoint actions, assessment and limitations.

NICU infection prevention now has 33 reference entries from the CDC February 2022 CLABSI guideline and August 2020 S. aureus guideline, plus selected necessary CDC core, catheter and Contact Precautions prerequisites. These cover the two existing catalog entries, not all neonatal sepsis or every section of CDC’s general guidelines.

All 22 numbered CLABSI recommendations and 11 S. aureus subrecommendations were inspected with their implementation conditions, risks, evidence confidence and unresolved questions. The linked evidence appendices contain research/search/GRADE tables; study regimens, enrollment cutoffs, associations and effect estimates are not relabeled as current care recommendations. Core baseline practices and local dependencies accompany conditional locks, bathing, surveillance and decolonization.

Jaundice and bilirubin now have 53 general reference records from the selected AAP guideline, 2024 technical report, implementation FAQ, CPS statement and NICE CG98. Screening, risks, treatment, monitoring, stopping, rebound, escalation and follow-up are available locally, with four result tables and 18 AAP numeric threshold grids.

AAP 2022 KAS 1–25 and written conditions, all 7 FAQ questions, 2024 technical sections and appendices, CPS Recommendations 1–29 plus Figures 1/4/5 and December 2025 addendum, and NICE clinical recommendations 1.1–1.10 were inspected. AAP 2022 versus 2024 stopping/rebound wording and CPS stopping boundaries remain explicit differences.

Low blood glucose now has 31 general reference records from CPS, ABM and BAPM, including seven locally readable static tables. CPS includes preterm newborns and distinguishes transition from persistence; ABM focuses on term/late-preterm breastfeeding care (its algorithm is ≥35 weeks); BAPM is term ≥37 weeks, birth–72 hours and excludes preterm/unwell intensive-care babies. Scope stays on every result.

The three sources were read through their recommendations, numerical tables, appendices and linked clinical algorithms. CPS’s < versus ≤2.8 investigation wording, ABM’s narrative/appendix timing and target differences, and BAPM’s threshold/time/transfer wording differences are explicitly retained. No date or app summary resolves clinical precedence.

US infant immunization · birth–23 months.

The accepted immunization collection covers US AAP and CDC childhood guidance for birth through 23 months. Routine, catch-up, conditional, and shared decision-making results are separately labeled. Extraction across the remaining source catalog is in progress; those source-only topics are interim and are not counted as completed recommendation coverage.

The 50 immunization records account for the infant portions of the selected schedules, including HepB, rotavirus, DTaP, Hib, pneumococcal conjugate, IPV, influenza, COVID-19, MMR, varicella, HepA, RSV antibodies, and indicated infant MenACWY. Routine timing is distinct from minimum catch-up timing. Ages beyond 23 months may be mentioned to explain later completion, not to claim coverage of the older-child schedule.

Agreement is claim-specific.

When recommendation, timing, category and applicability match, one summary shows a separately linked name for each supporting body. Matching a topic is not enough. Differences stay body-labeled: for example COVID-19 recommendation category, first-dose MMRV preference, second-season RSV risk groups, and infant MenQuadfi use.

AAP and CDC are attributed in immunization; CPS, ABM and BAPM in glucose; AAP, CPS and NICE in jaundice. Each result retains its own source and population. Organizations endorsing AAP’s schedule are not presented as independently issuing each paraphrased recommendation.

Currentness, without a misleading year.

AAP’s schedule is dated September 2, 2026. CDC’s live schedule notice explicitly identifies the July 2, 2025 child schedule as current. Its 2026–2027 COVID-19 and influenza clinical guidance, and RSV clinical guidance including clesrovimab, are separately dated and linked. An old formulation in an older Notes section is not silently carried into a new seasonal summary. Publication, revision and our source-check date are different facts.

Recommendation sources were checked October 27, 2026. The original 31 source listings were checked October 25, 2026. Checks are dated snapshots, not continuous monitoring or a guarantee that a later change has not appeared. No source date alone establishes clinical priority.

Scope and safety remain visible.

Each result shows its age/timing and recommendation category. Important conditions are on the card, with additional conditions and source dates available locally in its details disclosure. Read these conditions alongside local approved policies; the app does not decide whether a recommendation applies to an individual patient.

Official sources for the wider neonatal community.

The source directory is a selected collection, not an exhaustive inventory. Original guidelines and charts remain with the publisher; some sources need membership or sign-in. No unverified summary is generated in response to a search.

Corrections and review.

Summaries, source descriptions and search metadata are AI-assisted and checked against official passages. This does not claim independent clinician review, organizational affiliation, or endorsement. The independent product-review workflow is a separate verification step. Report an error with its official supporting passage; feedback remains private until reviewed.